Moderate Neuromuscular Blockade

Preclinical

Moderate Neuromuscular Blockade is one of 2 therapeutic programs targeting Inflammatory Cytokines. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Inflammatory CytokinesRecruiting

Inflammatory CytokinesPreclinical

Recruiting

Competition

Competitive Landscape

1 competitor in Inflammatory Cytokines

#DrugCompanyPhaseTrials

Calcium Intravenous Infsuion

MMansoura University

Preclinical

1 2

Moderate Neuromuscular Blockade

MMenoufia University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

PreclinicalRecruiting

Inflammatory Cytokines

NCT07485517

Clinical

Trials by Indication[1]

Inflammatory Cytokines1 trial

The Effect of Deep Versus Moderate Neuromuscular Blocking on Patients Undergoing Open Hysterectomy

Recruiting·MMenoufia University·Preclinical·NCT07485517·88 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Moderate Neuromuscular Blockade. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Moderate Neuromuscular Blockade. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Menoufia University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: MMenoufia University

Moderate Neuromuscular Blockade

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Inflammatory Cytokines1 trial

References

Drug Info

Quick Facts

Related News